Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
Globe Newswire•25/08/2026•01:00 ET
0
Whiz Insights
* DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027
* CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in 2027
Get started
Create a free account to read the full story.